These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8289395)

  • 1. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

  • 6. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.
    McDermott MR; Graham FL; Hanke T; Johnson DC
    Virology; 1989 Mar; 169(1):244-7. PubMed ID: 2538036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and sequence analyses of antibody-selected antigenic variants of herpes simplex virus show a conformationally complex epitope on glycoprotein H.
    Gompels UA; Carss AL; Saxby C; Hancock DC; Forrester A; Minson AC
    J Virol; 1991 May; 65(5):2393-401. PubMed ID: 1707982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
    Morrison LA; Knipe DM
    J Virol; 1994 Feb; 68(2):689-96. PubMed ID: 8289372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.
    Roop C; Hutchinson L; Johnson DC
    J Virol; 1993 Apr; 67(4):2285-97. PubMed ID: 8383241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
    Willey DE; Cantin EM; Hill LR; Moss B; Notkins AL; Openshaw H
    J Infect Dis; 1988 Dec; 158(6):1382-6. PubMed ID: 2848904
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.
    Chabalgoity JA; Khan CM; Nash AA; Hormaeche CE
    Mol Microbiol; 1996 Feb; 19(4):791-801. PubMed ID: 8820649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
    Zaia JA; Palmer EL; Feorino PM
    J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
    Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice.
    Mercadal CM; Slaoui M; Brown SM; Rouse BT
    Viral Immunol; 1993; 6(1):35-42. PubMed ID: 8386516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.